What is not working for the company?
What is working for the company?
|Name||Sep 22||Jun 22|
|Mutual Funds (Change:0.45)||6.26%||5.81%|
|Insurance Companies (Change:4.16)||4.16%||0%|
|Other DIIs (Change:-4.17)||0.52%||4.69%|
|Non Institution (Change:0.64)||19.27%||18.63%|
This tools helps you project your potential return on investments for the given stock, for a specified amount over a per-defined period of time.
If I had made LUMPSUM investment of ₹ 1,00,000
in Glenmark Pharmaceuticals Ltd
My investment would be worth ₹ 1,41,900 with a Gain of 41.90 %
Frequently Asked Questions
What is the Share price of GLENMARK PHARMACEUTICALS LTD. (GLENMARK)?
Can I buy GLENMARK PHARMACEUTICALS LTD. (GLENMARK) shares?
How do I buy GLENMARK PHARMACEUTICALS LTD. (GLENMARK) from Angel One?
- Direct investment: You can buy GLENMARK PHARMACEUTICALS LTD. (GLENMARK) shares by opening a Demat account with Angel One.
- Indirect investment: The indirect method involves investing through ETFs and Mutual Funds that offer exposure to GLENMARK PHARMACEUTICALS LTD. (GLENMARK) shares.
In which sector do GLENMARK PHARMACEUTICALS LTD. (GLENMARK) belong?
Today's live share price for Glenmark Pharmaceuticals Ltd is NSE: ₹ 434.95, BSE: ₹ 434.55 with a current market capitalization of .
Glenmark Pharmaceuticals Ltd is a research-driven, global, integrated pharmaceutical company. The company is a leading player in the discovery of new molecules both NCEs (new chemical entity) and NBEs (new biological entity) with five molecules in various stages of clinical development. The company has a significant presence in branded generics markets across emerging economies including India. The company engaged in discovery of new molecules both new chemical entities (NCEs) and new biological entities (NBEs). The company operates in five geographical areas: India, United States, Latin America, Europe and Rest of the World. They operate in three segments: specialty, generics and out-licensing. Specialty segment includes manufacture and distribution of branded products of Glenmark. Specialty business is focused on range of therapeutic segments, such as dermatology, internal medicine, respiratory, pediatrics, diabetes, gynecology, oncology. Generics segment consists of finished pharmaceutical products ready for consumption by the patient, marketed under as generic finished dosages with therapeutic equivalence to branded formulations (generics). Out-licensing segment includes the discovery of new chemical entities for subsequent commercialization and out-licensing, as well as contract research services. Glenmark Pharmaceuticals Ltd was incorporated in the year 1977. In the year 1979, the company entered dermatology market with the launch of "Candid Cream". In the year 1980, they started exporting their products. In the year 1983, the company commissioned their first manufacturing facility at Nasik in Maharashtra. In they ear 1984, they established R&D department at Nasik Plant. In the year 1987, they launched Ascoril. In the year 1989, the company started operations in Afghansitan, Srilanka, Kenya and Mauritius. In the year 1982, the company expanded the Nasik plant by acquiring the adjacent plot to include the R&D Department as well as increase in installed production capacity. In the year 1996, the company incorporated a wholly owned subsidiary company namely, Glenmark Exports Pvt Ltd to consolidate their position in international business. In the year 1999, they started marketing their products in Brazil. In the year 2000, they came out with the public issue. They entered in diabetes segment. Also, they acquired three brands from Lyka Labs. In the year 2001, the company launched API manufacturing business. In the year 2002, they acquired an API manufacturing facility at Ankleshwar, Gujarat from Glaxosmithkline Pharmaceuticals Ltd. In the year 2004, the company entered their first out-licensing deal for discovery R&D with Forest Laboratories for Oglemilast, their CIPD/asthma molecule. They acquired Laboratories Klinger, Brazil together with their ANVISA approved manufacturing facility inorder to expand their operations in the Latin American markets. They commissioned their own manufacturing facility at Goa to service exports to regulated markets, namely USA. In the year 2005, the company launched commercial sales front-end in the US. They commissioned a new manufacturing facility at Baddi, Himachal Pradesh. They entered collaborative agreement on Oglemilast with Teijin Pharma for the Japan region. Also, they announced collaborative agreement with Napa Pharmaceuticals Inc, for their anti-diarrheal compound Crofelemer. The company acquired Servycal S A, a marketing company in Argentina with strengths in oncology. Also, they acquired Bouwer Bartlett Pty Ltd, a sales and marketing company in South Africa. In the year 2006, the company signed out-licensing deal in discovery R&D with Merck KGaA, Germany for their diabetes molecule, Melogliptin. Their lead molecule Oglemilast (GRC 3886) entered Phase II clinical trials. In the year 2007, the company acquired Medicamenta, a marketing and manufacturing company in the Czech Republic. Their molecule GRC 6211 for the potential treatment of pain, including osteoarthritis pain out-licensed to Eli Lily. They received MHRA, UK approval for their semi-solid manufacturing plant at Baddi. In the year 2008, the company initiated Phase II-b for Oglemilast (GRC 3886) in Asthma. They completed preclinical development for initiating phase I trials for GBR 500, a monoclonal antibody for inflammation. The company`s molecule for Rheumatoid Arthritis, GRC 4039, entered Phase I trials. They re-organized their business and incorporated Glenmark Genrics Ltd as a subsidiary company. They received USFDA approval for the state-or-the-art semi-solids manufacturing plant at Baddi. In the year 2009, the company`s molecule for neurophatic pain, osteoarthritis, completed the Phase I trials. During the year 2009-10, the company incorporated a subsidiary company, namely Glenmark Generics B.V., Netherlands. In the year 2010, Crofelemer, a first-in-class anti-diarrhoeal molecule completed phase 3 trials. They received the final approval for Pramipexole Dihydrochloride tablets from the USFDA. Glenmark Generics entered into an exclusive licensing agreement with Par Pharmaceuticals, USA to market Ezetimibe. The company and Sanofi-Aventis signed license agreement to grant Sanofi-Aventis a license for the development and commercialization of novel agents to treat chronic pain. They launched "Prasugrel", a revolutionary new anti-platelet drug for the management of Acure Coronary Syundrome with PCT (Precutaneous Coronary Intervention) for the first time in India. During the year 2010-11, the company has incorporated a subsidiary company namely, Glenmark Arzneimittel GmbH, Germany. In October 2010, the company won the Frost and Sullivan award for "Indian Innovator Pharmaceutical Company of the year" in October 2010. The company was chosen as the "Best Company Across Emerging Markets" 2011, and recognized for the "Best Overall Pipeline" 2011 by SCRIP, the largest selling and most respected pharmaceutical magazine in the world. In 2012, Forest Laboratories and Glenmark Signed Development Agreement for Worldwide Collaboration on Novel Agents to treat Chronic Inflammatory Conditions. Glenmark Generics announces the settlement of Paragraph IV litigation with Janssen Pharmaceuticals, Inc. Glenmark Generics receives tentative approval for zolmitriptan orally disintegrating tablets. The International Centre for Dispute Resolution ruled in favor of Glenmark on arbitration claim against Napo. In 2013, Glenmark announces launch of Hydrocortisone Butyrate cream in the US. Glenmark announces a new Discovery and the Initiation of IND enabling studies of a novel monoclonal antibody targeting OX40. The USFDA approves the companies Crofelemer 125 mg delayed-release tablets for the symptomatic relief of diarrhea in patients with HIV/AIDS on anti-retroviral therapy (ART). Glenmark Generics receives ANDA approval for Mupirocin Calcium Cream USP 2%. Atovaquone Prognanil (Malarone) patent revoked & Glenmark launches first UK generic. Glenmark discovers IND enabling studies of a novel monoclonal antibody. In 2014, Glenmark merge its subsidiaries i.e. Glenmark Generics Ltd. ("GGL") and Glenmark Access Ltd. ("GAL") with GPL. Glenmark enters Oncology with the Discovery and the Initiation of IND enabling Studies of an innovative bispecific Antibody. Glenmark Pharmaceuticals inaugurates new Antibody Manufacturing Facility in La Chaux-de-Fonds, Switzerland. US Food & Drug Administration (US FDA) has granted Glenmark its final acceptance for abbreviated new drug approval (ANDA) to the company. Glenmark Pharma receives $5 mn from Sanofi as milestone payment from Sanofi on a collaboration of its VLA2 (alpha2-beta l) integrin monoclonal antibody. Glenmark Generics gets USFDA nod for skin infection cream. In 2015, Glenmark Pharmaceuticals Ltd announces approval and launch of Ashlyna TM Extended - Cycle Oral Contraceptive Tablets in the US. Glenmark Pharmaceuticals Ltd announces approval and launch of Trandolapril & Verapamil Hydrochloride (HCI). Glenmark Pharma gets US FDA nod for Salmecort MDI Inhaler in Russia. The Cabinet Committee on Economic Affairs (CCEA) headed by PM approves the foreign investment proposals of two pharma majors Glenmark Pharmaceuticals and Aurobindo Pharma worth Rs 4,187 crore. Glenmark Pharmaceuticals Ltd. has certified approving the Scheme of Arrangement of Glenmark Generics Ltd. and Glenmark Access Ltd. with Glenmark Pharmaceuticals Ltd. Glenmark announces Strategic Development & Licensing Agreement with Celon, Poland for generic Seretide Accuhaler in Europe. Glenmark Pharmaceuticals receives tentative ANDA approval for Lacosamide Tablets, 50 mg, 100 mg, 150 mg and 200 mg. Glenmark Pharmaceuticals receives ANDA approval for Clotrimazole and Betamethasone Dipropionate Cream USP, 1% | 0.05%. Glenmark Pharmaceuticals has entered into a settlement agreement with Forest Laboratories, LLC, Forest Laboratories Holdings, Ltd., and Royalty Pharma.Read more